342 related articles for article (PubMed ID: 25463089)
1. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress.
Battelli MG; Polito L; Bolognesi A
Atherosclerosis; 2014 Dec; 237(2):562-7. PubMed ID: 25463089
[TBL] [Abstract][Full Text] [Related]
2. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
[TBL] [Abstract][Full Text] [Related]
3. Mice heterozygous for the xanthine oxidoreductase gene facilitate lipid accumulation in adipocytes.
Murakami N; Ohtsubo T; Kansui Y; Goto K; Noguchi H; Haga Y; Nakabeppu Y; Matsumura K; Kitazono T
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):44-51. PubMed ID: 24158515
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
Polito L; Bortolotti M; Battelli MG; Bolognesi A
Pharmacol Res; 2022 Oct; 184():106407. PubMed ID: 35995347
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme.
Battelli MG; Bolognesi A; Polito L
Biochim Biophys Acta; 2014 Sep; 1842(9):1502-17. PubMed ID: 24882753
[TBL] [Abstract][Full Text] [Related]
6. Xanthine Oxidoreductase in the Pathogenesis of Endothelial Dysfunction: An Update.
Mudgal R; Singh S
Curr Hypertens Rev; 2024; 20(1):10-22. PubMed ID: 38318826
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Redox Biol; 2019 Feb; 21():101070. PubMed ID: 30576922
[TBL] [Abstract][Full Text] [Related]
8. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
9. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
[TBL] [Abstract][Full Text] [Related]
10. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.
Berry CE; Hare JM
J Physiol; 2004 Mar; 555(Pt 3):589-606. PubMed ID: 14694147
[TBL] [Abstract][Full Text] [Related]
11. Nitrite-mediated reduction of macrophage NADPH oxidase activity is dependent on xanthine oxidoreductase-derived nitric oxide but independent of S-nitrosation.
Zollbrecht C; Persson AE; Lundberg JO; Weitzberg E; Carlström M
Redox Biol; 2016 Dec; 10():119-127. PubMed ID: 27744114
[TBL] [Abstract][Full Text] [Related]
12. Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase.
Kelley EE
Arch Toxicol; 2015 Aug; 89(8):1193-207. PubMed ID: 25995007
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction.
Pinheiro LC; Oliveira-Paula GH; Portella RL; Guimarães DA; de Angelis CD; Tanus-Santos JE
Redox Biol; 2016 Oct; 9():134-143. PubMed ID: 27521759
[TBL] [Abstract][Full Text] [Related]
14. Association of Plasma Xanthine Oxidoreductase with Arterial Stiffness in Type 2 Diabetes with Liver Dysfunction.
Ohira M; Tanaka S; Watanabe Y; Nakamura S; Oka R; Yamaguchi T; Ban N; Saiki A; Ishihara N; Murano T; Murase T; Nakamura T; Tatsuno I
Am J Med Sci; 2022 Mar; 363(3):242-250. PubMed ID: 34619144
[TBL] [Abstract][Full Text] [Related]
15. Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling.
Agarwal A; Banerjee A; Banerjee UC
Crit Rev Biotechnol; 2011 Sep; 31(3):264-80. PubMed ID: 21774633
[TBL] [Abstract][Full Text] [Related]
16. Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity.
Cheung KJ; Tzameli I; Pissios P; Rovira I; Gavrilova O; Ohtsubo T; Chen Z; Finkel T; Flier JS; Friedman JM
Cell Metab; 2007 Feb; 5(2):115-28. PubMed ID: 17276354
[TBL] [Abstract][Full Text] [Related]
17. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
[TBL] [Abstract][Full Text] [Related]
18. Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes.
Okuyama T; Shirakawa J; Nakamura T; Murase T; Miyashita D; Inoue R; Kyohara M; Togashi Y; Terauchi Y
Sci Rep; 2021 Feb; 11(1):3768. PubMed ID: 33580173
[TBL] [Abstract][Full Text] [Related]
19. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.
Liu N; Xu H; Sun Q; Yu X; Chen W; Wei H; Jiang J; Xu Y; Lu W
Oxid Med Cell Longev; 2021; 2021():1470380. PubMed ID: 33854690
[TBL] [Abstract][Full Text] [Related]
20. Xanthine oxidoreductase activation is implicated in the onset of metabolic arthritis.
Aibibula Z; Ailixiding M; Iwata M; Piao J; Hara Y; Okawa A; Asou Y
Biochem Biophys Res Commun; 2016 Mar; 472(1):26-32. PubMed ID: 26903297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
